Lung-cancer screening currently relies largely on low-dose CT scans. These tests can catch tumours before symptoms appear, but they use X-rays and often flag harmless spots. Ordinary chest X-rays miss even more potential concerns, so researchers keep looking for checks that find the disease early without radiation exposure.
A new mouse study in Science Advances has now tested a path with a different kind of scan. Instead of X-rays, the team used an MRI machine that makes pictures with magnets and radio waves. They added a special dye that sticks to collagen — a tough protein the body uses to build and mend tissue. Some aggressive lung tumours lay down extra collagen at their edges, like a scar around a wound. In small groups of mice (53 in total), the dyed MRI scan picked up tumours and tiny deposits in the lungs and in nearby organs.
Some spots were about a millimetre wide. In those animals the new dye beat both a CT scan and a standard MRI dye, and it did so without radiation. That is the appeal of this early-stage new technique. If a similar scan ever worked in people, doctors might see small tumours and early spread without sending X-rays through the chest. The authors also hope the pictures could show how invasive a tumour looks, which might one day help them decide who needs a closer look.
“Our technology can detect tiny tumors and hidden metastases without exposing patients to radiation,” said study lead Dr. Jenny J. Yang in a news release from Georgia State University. “It also helps reveal how aggressive a cancer may be and how likely it is to spread, potentially reducing the need for invasive biopsies.”
The study sits in a wider push for less invasive and harmful checks. Clinics still rely on low-dose CT for people at high risk, but many want a first-pass test that does not use radiation at all. Some are trying breath and blood instead of pictures. Breath Diagnostics is developing OneBreath, which reads chemicals in a single exhaled breath. Other groups are progressing blood tests that hunt cancer traces in a vial of blood. None of those tools has replaced the CT screen, but they show why a radiation-free MRI dye has also drawn interest.
“This technology holds potential for early diagnosis, staging, disease monitoring, and drug discovery, without harmful radiation,” the researchers wrote in the study.
The mouse results are still a long way from a clinic though. The authors compared their dye with CT and a common MRI dye in small, anaesthetised groups of mice. They say people still need official safety trials. A scan like that is not the same as actually screening patients.
“We acknowledge potential limitations in the translatability of our system in patients, depending on the long Investigational New Drug application process with multi-dose levels of toxicity in small and large animal based on FDA guidance,” the authors also stated in Science Advances.
The dye’s target is another problem. Collagen is not unique to cancer. The body also piles it up in ordinary scars and in damaged or stiffened lungs. This same research group has already used a similar dye to picture lung scarring that was not cancer. Their new paper does not show that a scarred, cancer-free lung would stay dark. A bright patch on the scan might be a tumour. It might also be old damage.
The business ties deserve consideration too. Jenny J. Yang, the senior scientist, owns shares in InLighta Biosciences, holds the patents and licensed the dye to that firm. The paper clearly discloses this. Until another lab repeats the work, the boldest claims should be treated as early, interested-party science.
This study also does not show how often the dye would light up something that is not cancer, or whether that would spare people extra tests. A brighter mouse scan is not yet a superior screening programme.
Research in discussion was completed through a collaboration between Georgia State, The University of Alabama at Birmingham and Emory University. It was partially funded by the National Institutes of Health.
Read more: Breath Diagnostics advances pre-op pneumonia screening with FDA breakthrough designation
Follow Rowan Dunne on LinkedIn
rowan@mugglehead.com
